The US biotech firm Moderna said Tuesday it would enter the final stage of its human trials for its COVID-19 vaccine on July 27, after promising early results were published in a journal.
The Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half will receive a placebo.
It is designed to learn whether the vaccine can prevent infection by the SARS-CoV-2 virus, or, if people still get infected, whether it can prevent the infection from progressing toward symptoms.
If they do get symptoms, the vaccine can still be considered a success if it stops severe cases of COVID-19.
The study should run until October 27, according to its page on clinicaltrials.gov.
The announcement came after the New England Journal of Medicine on Tuesday published results from the first stage of Moderna’s vaccine trial, which showed the first 45 participants all developed antibodies to the virus.
Source: Channels TV